Sage Therapeutics, Inc.
US ˙ NasdaqGM ˙ US78667J1088
DENNA SYMBOL ÄR INTE LÄNGRE AKTIV

SecuritySAGE / Sage Therapeutics, Inc.
InstitutionEasterly Investment Partners Llc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Easterly Investment Partners Llc ownership in SAGE / Sage Therapeutics, Inc.

On July 29, 2025 - Easterly Investment Partners Llc filed a 13F-HR form disclosing ownership of 0 shares of Sage Therapeutics, Inc. (US:SAGE) valued at $0 USD as of June 30, 2025. The entity filed a previous 13F-HR on May 2, 2025 disclosing 27,000 shares of Sage Therapeutics, Inc.. The current value of the position is $0 USD.

Easterly Investment Partners Llc has a history of taking positions in derivatives of the underlying security (SAGE) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

SAGE / Sage Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-07-29 2025-06-30 13F SAGE THERAPEUTICS COM 78667J108 0 -100.00 0
2025-05-02 2025-03-31 13F SAGE THERAPEUTICS COM 78667J108 27,000 -18,000 -40.00 215 -12.30 0.0166
2025-02-12 2024-12-31 13F SAGE THERAPEUTICS COM 78667J108 45,000 -102 -0.23 244 -24.92 0.0192
2024-11-01 2024-09-30 13F SAGE THERAPEUTICS COM 78667J108 45,102 -91,500 -66.98 326 -78.08 0.0261
2024-07-25 2024-06-30 13F SAGE THERAPEUTICS COM 78667J108 136,602 27,000 24.63 1,483 -27.76 0.1304
2024-05-03 2024-03-31 13F SAGE THERAPEUTICS COM 78667J108 109,602 -13,041 -10.63 2,054 -22.73 0.1569
2024-02-14 2023-12-31 13F SAGE THERAPEUTICS COM 78667J108 122,643 -73,000 -37.31 2,658 -34.00 0.2842
2023-11-13 2023-09-30 13F SAGE THERAPEUTICS COM 78667J108 195,643 144,522 282.71 4,026 67.54 0.4430
2023-11-13 2023-06-30 13F SAGE THERAPEUTICS COM 78667J108 51,121 -29,524 -36.61 2,404 -28.97 0.2127
2023-11-13 2023-03-31 13F/A-1 SAGE THERAPEUTICS COM 78667J108 80,645 2,000 2.54 3,384 12.80 0.2978
2023-05-02 2023-03-31 13F SAGE THERAPEUTICS COM 78667J108 80,789 2,144 3,390 0.2343
2023-11-13 2022-12-31 13F/A-1 SAGE THERAPEUTICS COM 78667J108 78,645 14,980 23.53 3,000 20.30 0.2591
2023-02-10 2022-12-31 13F SAGE THERAPEUTICS COM 78667J108 78,501 14,836 2,994 0.2974
2022-11-09 2022-09-30 13F SAGE THERAPEUTICS COM 78667J108 63,665 -2,500 -3.78 2,493 16.66 0.2385
2022-08-10 2022-06-30 13F SAGE THERAPEUTICS COM 78667J108 66,165 32,555 96.86 2,137 92.18 0.1904
2022-05-13 2022-03-31 13F SAGE THERAPEUTICS COM 78667J108 33,610 33,610 1,112 0.0841
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-02-14 2023-12-31 13F SAGE THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-13 2023-09-30 13F SAGE THERAPEUTICS COM Call 10,000 -76.64 206 -89.81 n/a n/a n/a
2023-11-13 2023-06-30 13F SAGE THERAPEUTICS COM Call 42,800 2,012 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.